Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This randomized double blinded trial seeks to determine whether tranexamic acid (TXA) is an
efficacious treatment for contraceptive induced menstrual changes (CIMC) including irregular,
bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (ENG implant).
Participants will be randomized into the TXA treatment arm or a placebo. They will begin
taking the medication after three consecutive days of bleeding. Participants will track their
bleeding using an automated text message service